Investigational drug · Phase 3
EN3835
Also called: KN3835
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Flexible Hammertoe, Semi-flexible Hammertoe, Plantar Fibromatosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
21
Any phase or sponsor naming "EN3835"
First trial start
2023
Nov 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EN3835", any sponsor or status.
Conditions studied
As listed on its trial records.
- Flexible Hammertoe
- Semi-flexible Hammertoe
- Plantar Fibromatosis
- Ledderhose Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "EN3835" as an intervention, largest first.
- Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)Pivotal-lookingRecruiting
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT07759362 · 554 participants (planned) · Start Aug 11, 2026 · Primary completion Dec 2027
Drug: KN3835 · For: Flexible Hammertoe; Semi-flexible Hammertoe
Sites: Tucson, Arizona; Corona, California; Encinitas, California · 25 sites in all
- Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)Pivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT03526549 · 483 participants · Start Apr 26, 2018 · Primary completion Oct 8, 2021
Drug: CCH-aaes · For: Edematous Fibrosclerotic Panniculopathy; Cellulite
Sites: Glendale, Arizona; Scottsdale, Arizona; North Little Rock, Arkansas · 42 sites in all
- Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT)Pivotal-lookingRecruiting
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT07846280 · 470 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 2028
Drug: KN3835 · For: Flexible Hammertoe; Semi-flexible Hammertoe
Sites: Tarzana, California; Pinellas Park, Florida; Sweetwater, Florida · 4 sites in all
- Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)Pivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT06151197 · 436 participants · Start Nov 28, 2023 · Primary completion Jun 9, 2026
Drug: EN3835 · For: Plantar Fibromatosis; Ledderhose Disease
Sites: Mesa, Arizona; Scottsdale, Arizona; Tucson, Arizona · 66 sites in all
- Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in WomenPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT03428750 · 423 participants · Start Feb 5, 2018 · Primary completion Sep 26, 2018
Drug: EN3835; Placebo · For: Edematous Fibrosclerotic Panniculopathy (Cellulite)
Sites: Scottsdale, Arizona; Encinitas, California; Long Beach, California · 26 sites in all
- Effectiveness and Safety of EN3835 in the Treatment of Cellulite in WomenPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT03446781 · 422 participants · Start Feb 8, 2018 · Primary completion Sep 26, 2018
Drug: EN3835; Placebo · For: Edematous Fibrosclerotic Panniculopathy (Cellulite)
Sites: Glendale, Arizona; North Little Rock, Arkansas; Beverly Hills, California · 25 sites in all
- EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)Pivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT02724644 · 375 participants · Start Feb 2016 · Primary completion Sep 2016
Drug: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM; Placebo Comparator · For: Edematous Fibrosclerotic Panniculopathy; Cellulite
Sites: Beverly Hills, California; Murrieta, California; Oceanside, California · 16 sites in all
- EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)Completed
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT02942160 · 259 participants · Start Oct 5, 2016 · Primary completion Jun 14, 2018
Drug: Collagenase Clostridium Histolyticum · For: Edematous Fibrosclerotic Panniculopathy; Cellulite
Sites: Beverly Hills, California; Murrieta, California; Oceanside, California · 15 sites in all
- A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)Pivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT06169319 · 231 participants · Start Jan 3, 2024 · Primary completion Sep 30, 2024
Drug: Collagenase Clostridium Histolyticum (CCH); Placebo · For: Plantar Fasciitis
Sites: Tucson, Arizona; Castro Valley, California; Corona, California · 39 sites in all
- Safety and Efficacy of EN3835 in Participants With Frozen ShoulderPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT04496167 · 198 participants · Start Jul 29, 2020 · Primary completion Apr 14, 2022
Drug: EN3835; Placebo · For: Adhesive Capsulitis; Frozen Shoulder
Sites: Birmingham, Alabama; Mobile, Alabama; Tucson, Arizona · 38 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Collagenase Clostridium Histolyticum-aaes Injections for Volumetric Change of Cellulite Dimples and Gluteal Contouring.
Hartman NN, Almukhtar RM, Wood ES, et al. · Dermatol Surg 2023
- A Phase I Clinical Trial to Assess Safety and Tolerability of Injectable Collagenase in Women with Symptomatic Uterine Fibroids.
Singh B, Sims H, Trueheart I, et al. · Reprod Sci 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.